Anti-Connective Tissue Growth Factor Antibody Treatment Reduces Extracellular Matrix production in Trabecular Meshwork and Lamina Cribrosa cells

Wallace DM, Clark AF, Lipson K, Andrews D, Crean J, O’Brien CJ.

Discoveries in Sight Research Laboratories, Devers Eye Institute, and Legacy Research Institute, Legacy Health, Portland, Oregon, United States of America.

PURPOSE: We have previously demonstrated elevated levels of Connective Tissue Growth Factor (CTGF/CCN2) in the aqueous humour (AqH) of pseudoexfoliation glaucoma (PXFG) patients when compared to cataract controls. Furthermore, there is a significant trabecular meshwork (TM) and lamina cribrosa (LC) fibrotic phenotype associated with glaucoma possibly driven by CTGF. The purpose of this study was to investigate the potential of anti-CTGF immunotherapy in glaucoma.

METHODS: Primary TM and LC cells were cultured from human donors with (GTM/GLC) and without (NTM/NLC) primary open angle glaucoma (POAG). AqH samples from PXFG, POAG and control cataract patients were applied to N/GTM and N/G LC cells in the presence or absence of a therapeutic, humanized monoclonal anti-CTGF antibody FG-3019 (10µg/ml) (FibroGen Inc.). Hydrogen peroxide, (H2O2) was also used as a stimulus. Expression of fibrotic genes (fibronectin-1, fibrillin-1, CTGF, collagen 1A1 and a-smooth muscle actin) was assessed by q-PCR. Protein expression of collagen 1A1 and a-smooth muscle actin was examined in N/G TM cells by SDS-PAGE. The modulatory effect of FG3019 (10µg/ml) and IgG (10µg/ml) were also assessed.

RESULTS: Treatment of cells with AqH from PXFG & POAG patients and H2O2 induced a significant (P<0.05) increase in expression of pro-fibrotic genes, which was significantly reduced by pre-treatment with FG-3019 (P<0.05). FG-3019 also reduced expression of a-smooth muscle actin and collagen 1A1 protein expression in N/G TM cells.

CONCLUSIONS: FG-3019 is effective in blocking extracellular matrix production in TM and LC cells thus supporting a role for the use of anti-CTGF immunotherapy in the treatment of glaucoma.


PMID: 24204045